Table 1:

Height analyses data and results.

Dataset	Clopidogrel	Statins	Vancomycin	Gentamicin	Tacrolimus	Cyclosporine
Subjects (n)	1,509	4,843	5,227	254	1,180	508
SNPs post-QC (n)	778,986	1,515,824	1,050,868	1,248,133	1,187,219	1,248,265
Female (n, (%))	328 (21.7)	1,788 (36.9)	2,293 (43.9)	143 (56.3)	449 (38.1)	208 (40.9)
Age (mean, (SD), years)	63.0 (11.1)	NA	53.0 (13.6)	43.5 (15.7)	52.3 (12.0)	49.2 (14.2)
Height (mean, (SD), cm)	170.7 (8.8)	172.3 (10.5)	171.7 (10.7)	169.4 (12.2)	172.5 (10.2)	171.5 (10.4)
${\sigma }_g^2$	18.6	8.6	13.4	33.7	20.0	25.0
$h_{SNP}^2$	0.43 [0.00, 0.85]	0.19 [0.00, 0.42]	0.24 [0.00,0.46]	0.46 [0.00, 0.94]	0.41 [0.00, 0.85]	0.48 [0.00, 0.92]
Large effect variant (prop., (# SNPs))	0.06 (19)	0.05 (19)	0.04 (17)	0.32 (47)	0.10 (26)	0.21 (42)
Moderate-effect variant (prop., (# SNPs))	0.21 (215)	0.39 (363)	0.38 (377)	0.34 (302)	0.45 (400)	0.33 (322)
Small-effect variant (prop., (# SNPs))	0.74 (6,468)	0.55 (4,976)	0.57 (5,079)	0.34 (3,145)	0.46 (4,027)	0.45 (3,620)

SD – Standard Deviation; ${\sigma }_g^2$ – Additive Genetic Variance; $h_{SNP}^2$ - Narrow-sense Heritability, with conventionally calculated high density credible interval shown in brackets. Prop.: Proportion contributed to total $h_{SNP}^2$. NA indicates data not available.